Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells

Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases

(2016) M Thorn et al.   CANCER GENE THERAPY

Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline

(2016) P-P Liu et al.   ONCOGENE

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

The Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo

(2015) Julianna Blagih et al.   IMMUNITY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

(2015) Alexander M. Lesokhin et al.   Science Translational Medicine

Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells

(2015) Maria Peiris-Pagès et al.   Oncotarget

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

(2013) Joel Crespo et al.   CURRENT OPINION IN IMMUNOLOGY

PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients

(2013) Y. Liu et al.   JOURNAL OF NEUROSCIENCE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epstein–Barr virus maintains lymphomas via its miRNAs

(2013) D T Vereide et al.   ONCOGENE

Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

(2012) Wan Zhang et al.   NATURE CELL BIOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Density Gradient Centrifugation Compromises Bone Marrow Mononuclear Cell Yield

(2012) Claudia Pösel et al.   PLoS One

Understanding the metabolic basis of drug resistance

(2011) Ubaldo E. Martinez-Outschoorn et al.   CELL CYCLE

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

DNA Damage-Mediated Induction of a Chemoresistant Niche

(2010) Luke A. Gilbert et al.   CELL

GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes

(2010) Simon Gaudreau et al.   CELLULAR IMMUNOLOGY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY